NIAID releases MDR/XDR Tuberculosis research agenda
... Diagnosin...NIAID DNA vaccine for H5N1 avian influenza enters human trial
... Unlike conventional flu vaccines, which are developed by growing the influenza virus i...NIAID media availability: Examining genetic variability of malaria parasite offers insight
WHAT: Back-to-back papers published online this week in Nature Genetics reveal important new details about the genetic variability of the malaria parasite and provide new clues for how it causes disease. One paper, funded in part by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), reports the results of a massive effort to...NIAID awards $4 million to develop anti-radiation treatments
... "These new grants will help identify new drug candidates that could be acquired by the strategic national stockpil...Partnership between NIAID and Sequella yields promising new TB drug for clinical testing
... The success of one such public-private partnership has been demonstrated by Sequella, Inc...NIAID announces leadership for newly restructured HIV/AIDS clinical trials networks
... ... "The new network structure expands our clinical research capacity and strengthens our ability to take advantage of emerging scientific opportunities," says...NIAID study finds higher dose of flu vaccine improves immune response in the elderly
There may be a simple way to provide elderly Americans with extra protection against the annual flu virus: give them a higher dose of seasonal flu vaccine. This idea is suggested by the results of a newly reported clinical trial supported by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH)....... The trial, described in the...WHAT: The recent spread of deadly H5N1 influenza A virus among birds in Asia, Europe, and Africa has been the focus of much attention and concern worldwide--largely because of the danger that the virus will mutate into a form that will become easily transmissible from person to person. ...... In a March 16 article published online by Science, a research team led by scientists at The Scripps Resea...NIAID media availability: Understanding influenza infection
The current flu season is underway and much attention is focused on the recent outbreaks of a deadly avian influenza virus in Asia and southeastern Europe. Understanding how influenza viruses cause infection and how the human immune system attempts to fight off the invaders offers a basis for developing new influenza vaccines and treatments that could potentially combat seasonal influenza or wo...NIAID researchers show how promising TB drug works
Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined how a promising drug candidate attacks the bacterium that causes tuberculosis (TB). Published online this week in Proceedings of the National Academy of Sciences, the finding may help scientists optimize the drug candidate, PA-824, which targets Mycobacteri...NIAID awards $47 million to develop medical countermeasures against radiological, nuclear threats
The National Institute of Allergy and Infectious Diseases (NIAID) has issued more than $47 million for grants, contracts and interagency agreements as part of a new National Institutes of Health (NIH) research program on Medical Countermeasures Against Radiological and Nuclear Threats. This program emphasizes product development and seeks to develop preventions and treatments for radiation sickne...NIAID launches first Phase II trial of a 'global' HIV/AIDS vaccine
A novel vaccine targeted to multiple HIV subtypes found worldwide has moved into the second phase of clinical testing, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today. The study investigators plan to enroll a total of 480 participants at sites in Africa, North America, South America and the Caribbean to test the s...Large tularemia vaccine contracts among new NIAID biodefense awards
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced that it has recently made several dozen awards to further strengthen the nation's biodefense and emerging disease research capabilities. The new awards include grants totaling approximately $87 million for the construction of four biosafety level-3 (BSL-3) laboratories as...NIAID funds Center for HIV/AIDS Vaccine Immunology (CHAVI)
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced funding to establish the Center for HIV/AIDS Vaccine Immunology (CHAVI). Barton Haynes, M.D., of Duke University has been selected to lead the CHAVI consortium. The consortium may receive more than $300 million over seven years, $15 million of which is designated for its f...NIAID scientists unveil mechanism behind resistance to severe malaria
Scientists have discovered why people with a specific type of hemoglobin--the oxygen-carrying molecule that gives red blood cells their color--are less prone to severe malaria. In a series of experiments, the researchers determined how hemoglobin type C impairs the ability of malaria parasites to cause disease symptoms. ...... "This research gives us a new insight into malaria, a major global ki...New NIAID grants strengthen national biodefense and emerging infectious diseases research network
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four-year grants totaling approximately $80 million for two new Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE). The grants to the University of California, Irvine, and Colorado State University (Fort Collins) mark the completi...NIAID awards first $27 million using new bioshield authorities
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new therapeutics and vaccines against some of the most deadly agents of bioterrorism including anthrax, botulinum toxin, Ebola virus, pneumonic plague, smallpox and tularemia. ... ...Thes...A small trial testing the safety of an experimental vaccine targeting West Nile virus (WNV) opened today at the National Institutes of Health's (NIH) Clinical Center in Bethesda, MD. The vaccine, which will be tested first in 15 healthy adult volunteers, was developed for human clinical studies by researchers at the National Institute of Allergy and Infectious Diseases' (NIAID) Vaccine Research C...